Board of Directors
Maxime Ranger, Ph.D, MBA; Chairman of the Board
Dr Maxime Ranger is General Partner at AmorChem. He is Director of the Board of portfolio companies, such as Inversago Pharma, SemaThera, Mperia and MyX Therapeutics. Dr Ranger founded and managed a series of startup companies within Quebec’s ecosystem: Inversago Pharma (2015-present), gIcare pharma (2011-2015) with more than 10M$ raised in venture capital and GInova Pharma (2008-2011). Previously, he held management positions at Labopharm (2001-2003, acquired by Paladin, became Endo), Bioxalis Medica (2003-2004, acquired by Procyon, became Ambrillia) and Ecopia Bioscience (2004-2008, became Thallion, acquired by Bellus Health). Mr. Ranger has completed an Executive MBA at UQAM and Université Paris-Dauphine (2012), performed a postdoctoral fellow at Stanford University (2001) and holds a Ph.D. in chemistry, Material Sciences, from Laval University (2000).
Mitsuyoshi Azuma, PhD, Senju Pharmaceutical Co., Ltd.
Managing Executive Officer, Laboratory of Ocular Sciences; Clinical Research Professor, Oregon Health & Science University.
Garth Cumberlidge, PhD, SemaThera Inc.
Garth is the President & Chief Executive Officer of SemaThera. Additionally, he is chairman of the Board of Directors of Eyevensys, a French biotechnology company developing novel non-viral gene therapy platform for visionthreatening ocular diseases. He is the former President and Chief Executive Officer of Mimetogen Pharmaceuticals Inc., a biotechnology company developing novel neuroprotective and neurostimulatory compounds for the treatment of ocular diseases. Prior to Mimetogen, Dr. Cumberlidge served as President & CEO of Qbiogene Inc., a company providing life sciences research products and custom cGMP manufacturing services to academic, biotechnology and pharmaceutical researchers worldwide. Dr. Cumberlidge holds degrees in Biochemistry and Genetics from the University of London (U.K.) and in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin (Germany).
Andreas Stahl, MD, Klinik fuer Augenheilkunde, Universitaetsmedizin, Greifswald.
Prof. Dr. Andreas Stahl began his clinical career at the Freiburg University Eye Clinic. Research residencies in 2004 and 2008 – 2010 at Harvard Medical School, Boston (USA). Since 2014, he has headed the Department of Outpatient Retinal Surgery in Freiburg. His medical focus lies in the entire spectrum of conservative and operative retinology. Prof. Stahl is the author of numerous specialist publications and clinical therapy studies as well as a member of the Executive Board of the German Retinological Society. He is also a guideline officer for the screening and treatment of retinopathy of prematurity.